nVent Electric vs Smith & Nephew plc — how do they compare? nVent Electric trades at $161.42 (market cap $26.58B), while Smith & Nephew plc trades at $27.29 (market cap $11.10B). The key difference: nVent Electric is far larger — about 2.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold nVent Electric for 11 Days and Smith & Nephew plc for 120 Days on average.
| NVT | SNN | |
|---|---|---|
Market Cap | $26.58B | $11.10B |
Volume | 2,520,678 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $184.34 | $37.17 |
52-Week Low | $94.99 | $26.42 |
Typical Hold Time | 11 Days | 120 Days |
Enterprise Value | $27.95B | $14.13B |
Dividend Yield | 0.51% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Trailing returns across standard periods
Latest headlines on both assets
nVent provides electrical connection and protection solutions, including enclosures, fastening systems, and thermal management products. Its products help support electrical and industrial infrastructure across multiple end markets.
Read more on NVT →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →